🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Truist cuts Astronics stock target, hold rating on Boeing pressures

EditorNatashya Angelica
Published 18/10/2024, 14:30
ATRO
-

On Friday, Truist Securities adjusted its outlook on shares of Astronics (NASDAQ:ATRO) Corporation (NASDAQ:ATRO), a provider of aerospace and defense products, by reducing the price target to $20.00 from the previous $22.00, while maintaining a Hold rating on the stock.

The revised price target comes as the company management has guided third-quarter 2024 revenues to be in the range of $195 million to $205 million, anticipating refinancing expenses around $7.5 million. The adjustment by Truist reflects concerns over ongoing aircraft delivery pressures and the potential risk of a strike at Boeing (NYSE:BA), which could impact Astronics' operations.

Astronics' commercial aerospace offerings are considered short-cycle, which means they are susceptible to quick changes in demand. This nature of the business adds to the risk of inventory accumulation and could place pressure on the company's free cash flow, as highlighted by the firm.

The forecast by Truist indicates caution due to the current aerospace industry challenges that Astronics is facing. These include the immediate pressures from its key client, Boeing, which is experiencing its own operational hurdles.

The company's financial performance and outlook are closely tied to the health of the aerospace sector, particularly to aircraft manufacturers like Boeing. As such, any disruptions in aircraft deliveries or production can have a significant impact on Astronics' revenue streams and financial stability.

In other recent news, Astronics Corporation announced the appointment of Nancy L. Hedges as its new Vice President and Chief Financial Officer, succeeding the retiring David C. Burney. This comes alongside the company's robust Q2 performance, with sales hitting a notable $198 million, mirroring pre-pandemic levels.

Astronics also completed a refinance in July, leading to a lower interest rate, improved liquidity, and more favorable covenants. These are part of the company's latest developments.

Moreover, the company aims for double-digit operating profit and anticipates the Test segment to approach breakeven by the end of the year. The firm also projects mid-teens EBITDA margins and improved cash flow in the second half of the year.

Despite these positive forecasts, Astronics faced some challenges, including $1.3 million in restructuring and severance costs and an additional $3.5 million in estimated costs from mass transit test contracts. However, Astronics remains hopeful about resolving litigation matters by the end of 2025, potentially reducing future expenses.

InvestingPro Insights

Recent InvestingPro data provides additional context to Truist Securities' cautious stance on Astronics Corporation (NASDAQ:ATRO). Despite the reduced price target, InvestingPro Tips highlight that Astronics' net income is expected to grow this year, and analysts predict the company will be profitable. This optimism contrasts with the current financial situation, as the company was not profitable over the last twelve months, with a P/E ratio of -61.18.

The aerospace industry's volatility is reflected in Astronics' stock performance, with InvestingPro data showing a significant 31.5% price increase over the last six months. This aligns with the "short-cycle" nature of Astronics' commercial aerospace offerings mentioned in the article, demonstrating the company's sensitivity to market changes.

InvestingPro Tips also indicate that Astronics' liquid assets exceed short-term obligations, which could provide some financial flexibility as the company navigates the challenges highlighted by Truist Securities, including potential inventory accumulation and free cash flow pressures.

For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips for Astronics Corporation, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.